Search 

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; color: #454545}

MediSieve spun-out from University College London in 2015 to develop and commercialise magnetic blood filtration. The company has raised a total of £2.1M in equity funding and won grants worth a total of over £2M from the Wellcome Trust, Innovate UK, NIHR i4i and the EU Horizon 2020 SME Instrument. With the ability to specifically and selectively remove disease causing agents from the blood, magnetic blood filtration has the potential to transform the treatment of blood borne diseases. The company’s initial targets include Sepsis, Leukaemia and Malaria. Located in the new Imperial College Translation and Innovation Hub in White City, the company is preparing for first in man trials in 2019.

Microbiotica is founded on ground-breaking microbiome science from the Wellcome Sanger Institute, Cambridge UK. The company has unique capabilities to isolate all gut bacteria from any human and to identify gut bacterial signatures linked to patient phenotype from large clinical datasets with unprecedented precision. The business strategy is to use these to identify and progress best-in-class live bacterial therapeutics and to partner for drug-response biomarkers. The initial focus is in programs for IBD and Immuno-oncology, driven by best-in-class clinical datasets. The company has a $534m commercial partnership with Genentech, and clinical collaborations with Univ of Adelaide and Cambridge University Hospitals.